Walewski

Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma versus therapy in

E. Campo, J. Radford, L. Arcaini, 2020 .